

1 **Inflammation and fibrinolysis in loiasis before and after ivermectin treatment: a biological**  
2 **pilot cross-sectional study.**

3 Tristan M. Lepage<sup>1,2</sup>, Narcisse Nzune-Toche<sup>3</sup>, Lucie A. Nkwengoua<sup>4</sup>, Hugues C. Nana-  
4 Djeunga<sup>3</sup>, Sebastien D.S. Pion<sup>2</sup>, Joseph Kamgno<sup>3,4</sup>, Charlotte Boullé<sup>1,2</sup>, Jérémy T. Campillo<sup>2</sup>,  
5 Michel Boussinesq<sup>2</sup>, Claude T. Tayou<sup>4,5</sup>, Cédric B. Chesnais<sup>2\*</sup>

6  
7 <sup>1</sup> Department of Infectious and Tropical Diseases, Montpellier University Teaching Hospital,  
8 Montpellier, France

9 <sup>2</sup> TransVIHMI, Montpellier University, INSERM Unité 1175, Institut de Recherche pour le  
10 Développement (IRD), Montpellier, France

11 <sup>3</sup> Higher Institute of Scientific and Medical Research (ISM), Yaoundé, Cameroon

12 <sup>4</sup> Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Cameroon

13 <sup>5</sup> Hematology laboratory, Yaoundé University Teaching Hospital, Yaoundé, Cameroon

14

15 \*Correspondence: [cedric.chesnais@ird.fr](mailto:cedric.chesnais@ird.fr)

16 Institut de recherche pour le développement (IRD)

17 911 avenue Agropolis, 34000 Montpellier, France

18

19 **Word count**

20 Text 1955/2000 words

21 Abstract 97/100 words

22 **Abstract (97/100 words)**

23 We assessed the impact of loiasis and its treatment with ivermectin on hemostasis and inflammation  
24 in 38 adults in Cameroon. Participants were divided into four balanced groups based on their *Loa*  
25 *loa* microfilarial densities. At baseline, a positive correlation was observed between microfilarial  
26 densities, neutrophils (p=0.012) and eosinophils (p<0.001). At day 4 following ivermectin  
27 administration, mean D-dimers significantly increased, from 725 ng/mL to 1,276 ng/mL (p=0.024).  
28 Mean eosinophils rose from 225/ $\mu$ L to 1,807/ $\mu$ L (p<0.001). C-reactive protein, fibrinogen, and alpha-  
29 1-globulin also increased significantly after treatment. Ivermectin treatment appeared to induce  
30 inflammation and pronounced fibrinolysis, indicative of coagulation activation.

31

32 **Keywords**

33 Loiasis; Filariasis; Hemostasis; Inflammation; Fibrinolysis; Africa; Cameroon

34

## 35 **Background**

36 Loiasis, caused by the filarial nematode *Loa loa* and transmitted from human to human by  
37 tabanids, is exclusively endemic in central Africa. In infected individuals, adult female worms release  
38 embryos called microfilariae (mfs) which circulate in the bloodstream according to a diurnal cycle,  
39 with densities occasionally surpassing 100,000 mfs per mL of blood (mf/mL).

40 Although loiasis is historically considered as a benign disease, recent findings suggest that  
41 microfilaremic individuals have a significantly shortened life expectancy [1]. In addition, studies in  
42 the Republic of Congo showed that high *L. loa* microfilarial density (MFD) was significantly associated  
43 with proteinuria [2], cognitive impairment [3], and increased vascular stiffness [4].

44 Eosinophilia exceeding 5,000 / $\mu$ L is common among subjects with loiasis. Eosinophils, known  
45 to express tissue factor, may trigger blood coagulation [5], leading to thrombosis. Reports indicate  
46 that arterial and venous thrombotic events can occur in patients with parasite-related  
47 hypereosinophilia [6], with documented instances of thrombosis [7] and micro-emboli formation in  
48 capillary vessels [8], occurring both spontaneously and as part of post-ivermectin *Loa*-related serious  
49 adverse events (SAEs). Evidence from primate models suggests an association between post-  
50 ivermectin life-threatening encephalopathy and hemostatic dysregulation, characterized by  
51 degenerating mfs in small vessels associated with fibrin deposition, endothelial damages, and  
52 hemorrhages [9]. Similarly, humans experiencing post-ivermectin encephalopathy often exhibit  
53 conjunctival and retinal hemorrhages [10].

54 A potential dysregulation of hemostasis may contribute to the excess morbidity and  
55 mortality associated with loiasis. However, data on this phenomenon remain limited and unexplored  
56 in humans. The objective of the present study was to assess for the first time the impact of both *L.*  
57 *loa* MFD and its treatment with ivermectin (IVM) on human hemostasis and inflammation blood  
58 parameters.

59

## 60 **Methods**

61 *Study design and participants*

62 The study was conducted from July to December 2022 in two Health Districts of the Center Region of  
63 Cameroon (Mbalmayo and Awaé) where loiasis is highly endemic. Participants consisted of  
64 consenting adults aged 25 to 70 who had been screened for the presence of *L. loa* mfs. Exclusion  
65 criteria included pregnancy, concurrent pro-inflammatory conditions (such as infection, cancer or  
66 hematological disorder), current use of anticoagulant or anti-inflammatory medications, or known  
67 allergy to IVM. Eligible participants were stratified into 4 groups based on their *L. loa* MFD: 0 mf/mL;  
68 20–4,999 mf/mL; 5,000–19,999 mf/mL; and 20,000–40,000 mf/mL.

69 Venous blood samples were collected from all groups at baseline (D0) to measure hematological,  
70 hemostatic, and biochemical parameters. Subsequently, individuals in the 20–4,999 mf/mL and  
71 5,000–19,999 mf/mL groups received a single oral dose of IVM (150µg/kg), and the same blood  
72 parameters were reassessed four days after (D4) treatment.

73

74 *Sample size*

75 No data exists on the relationships between loiasis and hemostasis. In a study evaluating D-  
76 dimer levels in dogs infected with another filaria (*Dirofilaria immitis*) [11], the proportion of elevated  
77 D-dimers (>0.2 µg/ml) was 48% (22/46) in microfilaremic dogs, compared to 0% in amicrofilaremic  
78 dogs. Based on this finding, the inclusion of 16 *L. loa* microfilaremic subjects and 16 amicrofilaremic  
79 subjects would provide an 80% power with an alpha risk of 5% to detect such a difference in loiasis.  
80 However, it is difficult to extrapolate these assumptions to loiasis, which is a different disease with a  
81 different host. Therefore, we planned to include 10 *L. loa* amicrofilaremic subjects, and 30  
82 microfilaremic subjects in 3 groups of ascending MFD.

83

84 *Laboratory analyses*

85 Blood was collected by fingerprick between 10:00 am and 3:00 pm in non-heparinized  
86 capillaries and spread on microscope slides to prepare two 50 µL thick blood smears which were

87 dried, dehemoglobinized, and stained with Giemsa within 24 hours. *L. loa* mfs present on slides were  
88 counted using a microscope at 100-fold magnification at the Higher Institute for Scientific and  
89 Medical Research in Yaoundé, and averages of both slides were multiplied by 20 to express MFD per  
90 milliliter of blood.

91 Venous blood samples were collected from each participant using EDTA, sodium citrate, and  
92 dry blood tubes. Complete blood count, erythrocyte sedimentation rate (ESR) after one hour, C-  
93 reactive protein (CRP) levels, prothrombin time (PT), activated thromboplastin time, and fibrinogen  
94 levels were measured at the hematology laboratory of the Yaoundé University Teaching Hospital.  
95 Wright-stained blood smears were prepared and the percentage of eosinophils was recorded after  
96 examining 200 leukocytes. Eosinophil counts were calculated by multiplying the percentage of  
97 eosinophils by the white blood cell count.

98 Serum protein electrophoresis, ferritin and D-dimers were assessed at the Centre Pasteur in  
99 Yaoundé. Finally, prothrombin fragment F1+2 and plasminogen activity were evaluated in a subset of  
100 participants (10 without microfilariae and 10 with 20–40,000 mf/mL) at the Cerba Laboratory in  
101 France.

102

### 103 *Statistical analysis*

104 Hematological, hemostatic, and biochemical blood parameters were compared among the four MFD  
105 groups at baseline using the Kruskal-Wallis test. When the test yielded a p-value < 0.1, a Cuzick's test  
106 for trend was performed. Since D-dimers levels can be influenced by age and sex, the relationship  
107 between D-dimer and MFD was also assessed using a linear regression, with adjustments on age and  
108 sex. Prothrombin fragment F1+2 and plasminogen, assessed in a subset of 20 participants, were  
109 compared between amicrofilaremic and microfilaremic subjects using the Wilcoxon rank-sum test.  
110 Finally, within the groups of individuals treated with IVM (20–4,999 mf/mL and 5,000–19,999  
111 mf/mL), changes in hematological, hemostatic, and biochemical blood parameters were compared  
112 between baseline and D4 post-IVM using a Wilcoxon signed-rank test for paired observations.

113

114 *Ethical considerations*

115 The study adhered to ethical guidelines outlined in the Declaration of Helsinki, version 13, and was  
116 approved by the Ethics Committee for Human Research of the Catholic University of Central Africa  
117 (N° 2022/022503/CEIRSH/ESS/MH) and by Yaoundé University Teaching Hospital (N°  
118 4181/AR/CHUY/DG/DGA/CAPRC). Only individuals who provided informed consent were enrolled  
119 and assigned an individual code for data recording. Blood parameters results were shared with all  
120 participants.

121

122 **Results**

123 Twenty males and 18 females aged between 28 and 67 years (median age: 43 years old)  
124 participated in the study.

125 Table 1 presents the blood counts and the inflammation and hemostasis parameters  
126 according to the participants' *L. loa* MFD categories. There was a trend towards increased leucocytes,  
127 neutrophils and eosinophils counts with increasing MFD ( $p=0.011$ ,  $p=0.013$  and  $p<0.001$ ,  
128 respectively, Cuzick's tests for trend). The mean eosinophil count increased from  $118/\mu\text{l}$  in patients  
129 with no mf to  $1,079/\mu\text{l}$  in patients with a MFD beyond 20,000 mf/mL. Although the distribution of  
130 platelets varied significantly between groups, no trend was observed regarding MFD levels ( $p=0.055$ ,  
131 Cuzick's test for trend). Inflammation and hemostasis parameters did not significantly differ between  
132 groups. Linear regression analysis of D-dimers by MFD, adjusted on age and sex, did not show any  
133 significant associations. Mean ESR were consistently increased across all groups (normal values:  $< 20$   
134 mm/h). Gamma-globulin were also elevated in all groups, with means from 21 to 27 g/L (normal  
135 values:  $< 11$  g/L). Clonal gamma-globulin expression was suspected on the serum protein  
136 electrophoresis in 3 patients, each in separate groups.

137 Eighteen individuals with an MFD between 20 and 19,999 mf/mL received a single dose of  
138 IVM and were re-examined at D4 (Table 2). Post-treatment, the mean MFD significantly decreased

139 from 6,211 mf/mL to 2,972 mf/mL. Eosinophil count means rose from 225/ $\mu$ L to 1,807/ $\mu$ L ( $p < 0.001$ ).  
140 Various inflammation markers changed significantly: CRP, ESR, fibrinogen and alpha-1-globulin levels  
141 increased ( $p = 0.038$ ,  $p = 0.010$ ,  $p = 0.002$  and  $p = 0.044$ , respectively), while albumin level decreased  
142 ( $p = 0.044$ ). Among hemostatic parameters, mean D-dimers significantly increased, from 725 ng/mL to  
143 1,276 ng/mL after IVM ( $p = 0.024$ ) with a median relative variation of +34.7% (interquartile range:  
144 1.44-72.5%). Prothrombin fragment 1+2 mean increased from 315 to 435 pmol/L, but the difference  
145 was not statistically significant ( $p = 0.313$ ). No new clonal gamma-globulin expression on protein  
146 electrophoresis was suspected, while previously identified clonal expression in treated patients did  
147 not change after IVM.

148

## 149 Discussion

150 In this pilot biological study, we describe for the first time hemostasis and inflammation  
151 parameters associated with loiasis. Our results show a remarkable trend towards increased  
152 leukocytes, mainly driven by elevated eosinophils and neutrophils, with increasing *L. loa* MFD. In a  
153 2022 biological study in Gabon [12], eosinophil counts were also positively correlated with *L. loa*  
154 MFD, with an estimated increase in eosinophil counts every 10-fold increase in parasitemia ( $p$ -adj. =  
155 0.012,  $\beta$ -estimate: 0.17[0.04–0.31]). Chronic eosinophilia, a characteristic feature of loiasis, is known  
156 for its ability to trigger severe health conditions, such as endomyocardial fibrosis, tropical pulmonary  
157 eosinophilia, and thromboembolic events, consequently increasing the risk of mortality associated  
158 with loiasis [1].

159 The notable increase in neutrophils that correlates with increasing MFDs raises intriguing  
160 questions. Prior research has associated neutrophil recruitment with the presence of endosymbiotic  
161 *Wolbachia* bacteria in filarial infections (onchocerciasis and lymphatic filariasis) [13]. However, as *L.*  
162 *loa* mfs lack *Wolbachia* bacteria, alternative mechanisms must be considered to elucidate neutrophil  
163 involvement in loiasis.

164 Furthermore, our study highlighted a polyclonal elevation of gamma-globulins across all MFD  
165 groups, suggesting a systemic immune response. This phenomenon is consistent with a previous  
166 study in Ghana, where 75% of participants had gamma-globulins > 16 g/L [14]. This  
167 hypergammaglobulinemia might be explained by the influence of genetic as well as environmental  
168 factors. Mean ESR were increased in all groups, possibly driven by hypergammaglobulinemia, which  
169 is known to accelerate erythrocyte sedimentation.

170 Interestingly, while inflammation and hemostasis parameters did not significantly differ with  
171 *L. loa* MFD at baseline, treatment with IVM resulted in significant alterations in several inflammatory  
172 markers (such as CRP, ESR, fibrinogen and alpha-1-globulins). While post-IVM CRP increase has been  
173 reported previously [15], we document for the first time significant changes in a range of  
174 inflammatory parameters. We observed a marked increase in eosinophils, consistent with previous  
175 reports of interleukin-5 (IL-5)-driven eosinophilia following microfilarial killing by IVM [16].

176 The increase in D-dimers observed on D4 post-IVM suggests enhanced fibrinolysis and thus  
177 coagulation activation. This could be attributed to the close relationship between hemostasis and  
178 inflammation, where inflammation induces fibrin formation in the extravascular space, facilitating  
179 immune cells functions [17]. Consequently, secondary fibrinolysis generates D-dimers, which  
180 correlate with inflammation severity. However, this correlation is modest, as previous studies found  
181 a Spearman's correlation coefficient of 0.18 between CRP and D-dimers, indicating a limited  
182 response of D-dimers to CRP elevation [18]. Therefore, in addition to inflammation, the potential  
183 involvement of thrombotic processes in the increase of D-dimers after IVM cannot be ruled out,  
184 potentially both driven by intravascular dying mfs and inflammation-induced hypercoagulable  
185 condition.

186 In addition to previous reports of post-IVM retinal emboli [10], this hypothesis is supported  
187 by autopsies of post-IVM encephalopathies in baboon models, which show abnormalities ranging  
188 from intravascular degenerating mfs and vessel wall infiltration by immune cells such as eosinophils,  
189 to fibrin deposition and endothelial disruption with extravascular hemosiderin deposits [9,19]. These



190 findings provide a plausible pathological basis for the observed post-IVM treatment biological  
191 changes, potentially contributing to the pathogenesis of post-IVM SAEs.

192         Despite the valuable insights gained, our study has limitations. The small sample size and  
193 absence of preexisting data require cautious interpretation of our findings, highlighting the need for  
194 larger dedicated studies to validate our observations and understand their clinical implications.  
195 However, our results, particularly in baseline comparisons, may guide further research with adequate  
196 sample sizes, especially to explore the impact of loiasis on the hemostatic system. Additionally,  
197 potential confounding by other health conditions among participants, particularly in a low-resource  
198 healthcare setting, warrants consideration. Despite this, hematological changes showed a significant  
199 increase trend with *L. loa* MFD, aligning with previous findings [12]. However, as only *L. loa* MFD was  
200 assessed, potential confounding by other parasitic infections sensitive to IVM cannot be ruled out.  
201 Finally, our reliance on a single post-IVM evaluation timepoint may have limited our ability to detect  
202 biological abnormalities occurring outside this timeframe.

203         In conclusion, this pilot study identified several biological changes potentially associated with  
204 loiasis, occurring both spontaneously and after treatment with IVM. Further dedicated studies are  
205 needed to confirm these results, which might participate in loiasis excess mortality as well as post-  
206 IVM SAEs pathogenesis.

207

#### 208 **Authors contributions**

209 T.M.L, N.N.T., and L.A.N. carried out the cross-sectional study in 2021; C.B., M.B., C.T.T., and C.B.C  
210 designed the study; L.A.N. and C.T.T. performed hematological, hemostatic, and biochemical blood  
211 analyses; H.C.N.D. supervised parasitological analyses; N.N.T. and L.A.N. participated in the  
212 acquisition of data; T.M.L. and S.D.S.P. performed the statistical analyses; T.M.L. wrote the first  
213 version of the manuscript; H.C.N.D., C.B.C., M.B., S.D.S.P., C.T.T and J.T.C. reviewed the article. All  
214 authors approved the final version for publication.

215

## 216 **Funding**

217 This work was supported by the European Research Council (ERC) under the European Union's  
218 Horizon 2020 research and innovation program [grant agreement No 949963]. C.B.C. is the carrier of  
219 this grant.

220

## 221 **Role of the Funder/Sponsor**

222 The funders had no role in the design and conduct of the study; collection, management, analysis,  
223 and interpretation of the data; preparation, review, or approval of the manuscript; and decision to  
224 submit the manuscript for publication.

225

## 226 **Acknowledgements**

227 We thank all participants who agreed to take part in this study as well as the village chiefs and health  
228 workers involved.

229

## 230 **Conflict of Interests**

231 The authors declare that they have no competing interests.

232

## 233 **Data sharing**

234 Anonymized data will be hosted on the server <https://dataverse.ird.fr/>, and the terms of use will be  
235 those in force on the hosting site.

236

## 237 **References**

- 238 1. Chesnais CB, Takougang I, Paguélé M, Pion SD, Boussinesq M. Excess mortality associated with  
239 loiasis: a retrospective population-based cohort study. *Lancet Infect Dis.* **2017**; 17(1):108–116.
- 240 2. Campillo JT, Hemilembolo MC, Pion SDS, et al. Association between blood *Loa loa* microfilarial  
241 density and proteinuria levels in a rural area of the Republic of Congo (the MorLo project): a  
242 population-based cross-sectional study. *Lancet Microbe.* **2023**; 4(9):e704–e710.

- 243 3. Checkouri T, Missamou F, Pion SDS, et al. Association between altered cognition and *Loa loa*  
244 microfilaremia: First evidence from a cross-sectional study in a rural area of the Republic of  
245 Congo. *PLoS Negl Trop Dis.* **2023**; 17(6):e0011430.
- 246 4. Campillo JT, Dupasquier V, Lebredonchel E, et al. Association between arterial stiffness and *Loa*  
247 *loa* microfilaremia in a rural area of the Republic of Congo: A population-based cross-sectional  
248 study (the MorLo project). *PLoS Negl Trop Dis.* **2024**; 18(1):e0011915.
- 249 5. Moosbauer C, Morgenstern E, Cuvelier SL, et al. Eosinophils are a major intravascular location  
250 for tissue factor storage and exposure. *Blood.* **2007**; 109(3):995–1002.
- 251 6. Maino A, Rossio R, Cugno M, Marzano AV, Tedeschi A. Hypereosinophilic syndrome, Churg-  
252 Strauss syndrome and parasitic diseases: possible links between eosinophilia and thrombosis.  
253 *Curr Vasc Pharmacol.* **2012**; 10(5):670–675.
- 254 7. Petersen S, Rønne-Rasmussen J, Basse P. Thrombosis of the ulnar veins--an unusual  
255 manifestation of *Loa loa* filariasis. *Scand J Infect Dis.* **1998**; 30(2):204–205.
- 256 8. Corrigan MJ, Hill DW. Retinal artery occlusion in loiasis. *Br J Ophthalmol.* **1968**; 52(6):477–480.
- 257 9. Wanji S, Eyong E-EJ, Tendongfor N, et al. Ivermectin treatment of *Loa loa* hyper-microfilaraemic  
258 baboons (*Papio anubis*): Assessment of microfilarial load reduction, haematological and  
259 biochemical parameters and histopathological changes following treatment. *PLoS Negl Trop*  
260 *Dis.* **2017**; 11(7):e0005576.
- 261 10. Fobi G, Gardon J, Santiago M, Ngangue D, Gardon-Wendel N, Boussinesq M. Ocular findings  
262 after ivermectin treatment of patients with high *Loa loa* microfilaremia. *Ophthalmic Epidemiol.*  
263 **2000**; 7(1):27–39.
- 264 11. Carretón E, Corbera JA, Juste MC, Morchón R, Simón F, Montoya-Alonso JA. *Dirofilaria immitis*  
265 infection in dogs: cardiopulmonary biomarker levels. *Vet Parasitol.* **2011**; 176(4):313–316.
- 266 12. Veletzky L, Eberhardt KA, Hergeth J, et al. Distinct loiasis infection states and associated clinical  
267 and hematological manifestations in patients from Gabon. *PLoS Negl Trop Dis.* **2022**;  
268 16(9):e0010793.
- 269 13. Ajendra J, Allen JE. Neutrophils: Friend or foe in Filariasis? *Parasite Immunol.* **2022**;  
270 44(6):e12918.
- 271 14. Buadi F, Hsing AW, Katzmann JA, et al. High prevalence of polyclonal hypergamma-  
272 globulinemia in adult males in Ghana, Africa. *Am J Hematol.* **2011**; 86(7):554–558.
- 273 15. Ducorps M, Gardon-Wendel N, Ranque S, et al. Secondary effects of the treatment of  
274 hypermicrofilaremic loiasis using ivermectin. *Bull Soc Pathol Exot.* **1995**; 88(3):105–112.
- 275 16. Herrick JA, Legrand F, Gounoue R, et al. Posttreatment Reactions After Single-Dose  
276 Diethylcarbamazine or Ivermectin in Subjects With *Loa loa* Infection. *Clin Infect Dis.* **2017**;  
277 64(8):1017–1025.
- 278 17. Franchini M, Focosi D, Pezzo MP, Mannucci PM. How we manage a high D-dimer.  
279 *Haematologica.* **2024**; 109(4):1035–1045.

- 280 18. Crop MJ, Siemes C, Berendes P, Straaten F van der, Willemsen S, Levin M-D. Influence of C-  
281 reactive protein levels and age on the value of D-dimer in diagnosing pulmonary embolism. Eur  
282 J Haematol. **2014**; 92(2):147–155.
- 283 19. Kamgno J, Boussinesq M, Labrousse F, Nkegoum B, Thylefors BI, Mackenzie CD. Case report :  
284 Encephalopathy after ivermectin treatment in a patient infected with *Loa loa* and *Plasmodium*  
285 *spp.* Am J Trop Med Hyg. **2008**; 78(4):546–551.
- 286